{"id":39722,"date":"2021-09-29T11:25:04","date_gmt":"2021-09-29T11:25:04","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=79713"},"modified":"2021-09-29T11:25:04","modified_gmt":"2021-09-29T11:25:04","slug":"adagio-therapeutics-announces-new-data-highlighting-the-potential-of-adg20-for-treatment-and-prevention-of-covid-19","status":"publish","type":"post","link":"https:\/\/southafricatribune.com\/adagio-therapeutics-announces-new-data-highlighting-the-potential-of-adg20-for-treatment-and-prevention-of-covid-19\/","title":{"rendered":"Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19"},"content":{"rendered":"
\n

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study<\/em><\/p>\n

Data from Quantitative Systems Pharmacology\/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300 mg Intramuscular Dose of ADG20 Given as a Single Intramuscular Injection in Ongoing Phase 2\/3 Studies<\/em><\/p>\n

Data to be Presented During IDWeek 2021 and 19<\/em>th<\/em><\/sup> Annual Discovery on Target Conference<\/em><\/p>\n

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new data from the company\u2019s COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular (IM) dose given as a single injection that is being evaluated in the company\u2019s ongoing global Phase 2\/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of America\u2019s IDWeek 2021, being held from Sept. 29 \u2013 Oct. 3, 2021. In addition, Adagio\u2019s chief scientific officer, Laura Walker, Ph.D., will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimization of this differentiated antibody clinical candidate in an oral presentation at the 19th<\/sup> Annual Discovery on Target Conference on Sept. 30, 2021.<\/p>\n

\u201cThe continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 \u2013 which was designed to be potent, broadly neutralizing and delivered as a single IM injection \u2013 could have on people with or at risk of COVID-19,\u201d said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. \u201cThese Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of COVID-19. We anticipate these data will support an Emergency Use Authorization (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.\u201d<\/p>\n

Phase 1 Trial Update
\n<\/em><\/strong>Adagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics (PK), immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo<\/em> against SARS-CoV-2. Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection. In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. Importantly, ADG20 was well tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions reported through a minimum of three months follow-up across all cohorts. Participants will continue to be followed through 12 months to assess safety and tolerability, PK, immunogenicity and serum virus neutralizing activity.<\/p>\n

Phase 1 Poster Information: <\/strong>(633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)<\/p>\n

Dose Selection Strategy
\n<\/em><\/strong>To support dose selection for Adagio\u2019s global Phase 2\/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole-body physiologically-based pharmacokinetic (QSP\/PBPK) model to better characterize the PK of extended half-life monoclonal antibodies in serum and key sites of viral replication in the respiratory tract. Adagio\u2019s model adequately a priori<\/em> predicted the observed ADG20 serum PK in non-human primates (NHPs) and humans. The model was further optimized based on data from Adagio\u2019s Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE.<\/p>\n

For the STAMP treatment trial, data compiled to date suggest that the 300 mg IM regimen has a projected ability to rapidly achieve and maintain target concentrations at key tissue sites of viral replication, including the ability to attain near complete (> 90%) and durable (> 28-day) SARS-CoV-2 receptor occupancy across a range of baseline viral loads. Further, for the EVADE prevention trial, data compiled to date suggest the 300 mg IM regimen has a projected ability to rapidly exceed target serum concentrations in the majority of simulated patients and to maintain potentially effective concentrations for up to 12 months.<\/p>\n

Dose Selection Poster Information<\/strong><\/p>\n